| Name | Title | Contact Details |
|---|
Kezar co-founder Christopher Kirk, Ph.D. began his work on the unique function of the immunoproteasome at Proteolix in 2005, while working on the compound that would become the successful multiple myeloma drug KYPROLIS™ (carfilzomib). As VP of Research at Onyx Pharmaceuticals, which acquired Proteolix in 2009, Christopher led the efforts to develop the first selective inhibitors of the immunoproteasome and designed multiple studies demonstrating their profound immunomodulatory effects. In parallel with this work, Christopher and Kezar co-founder Jack Taunton, Ph.D. collaborated on several research projects involving protein secretion. This collaboration inspired a belief in the strong synergies between protein degradation and protein secretion, two fertile areas for drug discovery with platform potential. In 2014, Christopher and Kezar co-founder John Fowler began developing the business plan for Kezar, acting on a longstanding desire to work together and build a world-class company. In 2015, John and Christopher raised $23M and negotiated a worldwide, exclusive license agreement with Amgen for the Onyx immunoproteasome inhibitor patent estate. Now underway, John and Christopher are excited to leverage their complementary skill sets to build Kezar into a leader in small molecule drug development.
BioReliance Corporation is a contract service organization that provides services for biologics and other biomedical products to biotechnology and pharmaceutical companies worldwide. The Company has two segments, testing and development services and
Hoffmann-La Roche Inc. (Roche), based in Nutley, N.J., is the U.S. prescription drug unit of the Roche Group, a leading research-based health care enterprise that ranks among the world's leaders in pharmaceuticals, diagnostics and vitamins. Roche
Dharmacon Research is a Lafayette, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible. At SkylineDx we transform life sciences into the daily practice of clinical diagnostics. We enable patients to benefit sooner and safer from new insights in the molecular basis of disease. We can truly make a difference by making our love of life tangible as state-of-the-art diagnostic products with a high clinical value. Our products are designed to support clinicians in making the right choices for their patients. This provides a unique and very real difference. Obvious perhaps, but never taken for granted here at SkylineDx.